Publications:

Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.

Leukemia & Lymphoma

Gomez-Arteaga, Alexandra A; Margolskee, Elizabeth E; Wei, Mike T MT; van Besien, Koen K; Inghirami, Giorgio G; Horwitz, Steven S

Publication Date: 2019-07

Variant appearance in text: ATM: I1740N

PubMed Link: 30997845

Variant Present in the following documents:

• Main text

View BVdb publication page